Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks
The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Abstract
ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTIrreversible Protein Kinase Inhibitors: Balancing the Benefits and RisksTjeerd Barf* and Allard KapteinView Author Information Drug Discovery Unit, Covalution Pharma BV, Ravenstein, The Netherlands*Phone: +31 618 193139. E-mail, [email protected]Cite this: J. Med. Chem. 2012, 55, 14, 6243–6262Publication Date (Web):May 23, 2012Publication History Received7 March 2012Published online8 June 2012Published inissue 26 July 2012https://pubs.acs.org/doi/10.1021/jm3003203https://doi.org/10.1021/jm3003203review-articleACS PublicationsCopyright © 2012 American Chemical SocietyRequest reuse permissionsArticle Views13870Altmetric-Citations266LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Inhibition,Inhibitors,Kinase inhibitors,Monomers,Peptides and proteins Get e-Alerts
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the 1970s, researchers reported that covalent drugs produce hepatotoxicity resulting from off-target effects via unselectively modifying non-target proteins with their highly reactive groups [37, 45].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [45]
Citations
Cites
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Fibroblast growth factors, their receptors and signaling
Powers, C. J., McLeskey, S. W., & Wellstein, A. (2000) · Endocrine-related cancer · doi:10.1677/erc.0.0070165 · Cited by 1,332
Research works printed but not linked: 5
- Powis G., 1994, Cancer Res., 54, 2419
- Wood E. R., 2008, Proc. Natl. Acad. Sci. U.S.A., 105, 2772
- Brigdes A. J., 2000, Chem. Rev., 101, 2541
- Advani, R.; Sharman, J.; Smith, S.; Boyd, T.; Grant, B.; Kolibaba, K.; Furman, R.; Buggy, J.; Loury, D.; Hedrick, E.; Izumi, R.; Hamdy, A.; Fowler, N.The Btk Inhibitor PCI-32765 Is Highly Active and Well Tolerated in Patients with Relapsed/Refractory B Cell Malignancies: Final Results from a Phase I Study. Presented at the 11th International Conference on Malignant Lymphoma (ICML), Lugano, Switzerland, June 15–18, 2011.
- Petter, R.Targeted Covalent Kinase Inhibitors: AVL 292 as a Potent, Irreversible and Selective Inhibitor of Btk. Presented at the 5th Anglo-Swedish Medicinal Chemistry Symposium (ASMC), Åre, Sweden, March 20–23, 2011.
Cited by
Kinase-targeted cancer therapies: progress, challenges and future directions
Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0804-2 · Cited by 1,245
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
Liu, Q., Sabnis, Y., Zhao, Z., Zhang, T., Buhrlage, S. J., Jones, L. H., & Gray, N. S. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.12.006 · Cited by 652
Jackson, P. A., Widen, J. C., Harki, D. A., & Brummond, K. M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00788 · Cited by 588
Targeted Covalent Inhibitors for Drug Design
Baillie, T. A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601091 · Cited by 578
Bauer, R. A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.005 · Cited by 534
Polypharmacology: drug discovery for the future
Reddy, A. S., & Zhang, S. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.74 · Cited by 479
Zhao, Z., Wu, H., Wang, L., Liu, Y., Knapp, S., Liu, Q., & Gray, N. S. (2014) · ACS Chemical Biology · doi:10.1021/cb500129t · Cited by 433
Prolonged and tunable residence time using reversible covalent kinase inhibitors
Bradshaw, J. M., McFarland, J. M., Paavilainen, V. O., Bisconte, A., Tam, D., Phan, V. T., Romanov, S., Finkle, D., Shu, J., Patel, V., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1817 · Cited by 422
Barf, T., Covey, T., Izumi, R., van de Kar, B., Gulrajani, M., van Lith, B., van Hoek, M., de Zwart, E., Mittag, D., Demont, D., et al. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.242909 · Cited by 380
Self-citationAtropisomerism in Medicinal Chemistry: Challenges and Opportunities
Toenjes, S. T., & Gustafson, J. L. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0152 · Cited by 382
Enzyme Inhibitor Discovery by Activity-Based Protein Profiling
Niphakis, M. J., & Cravatt, B. F. (2014) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060713-035708 · Cited by 366
A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors
Lanning, B. R., Whitby, L. R., Dix, M. M., Douhan, J., Gilbert, A. M., Hett, E. C., Johnson, T. O., Joslyn, C., Kath, J. C., Niessen, S., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1582 · Cited by 359
Structure-based design of targeted covalent inhibitors
Lonsdale, R., & Ward, R. A. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00220c · Cited by 344
Flanagan, M. E., Abramite, J. A., Anderson, D. P., Aulabaugh, A., Dahal, U. P., Gilbert, A. M., Li, C., Montgomery, J., Oppenheimer, S. R., Ryder, T., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501412a · Cited by 320
Protein tyrosine phosphatases as potential therapeutic targets
He, R.-J., Yu, Z.-H., Zhang, R.-Y., & Zhang, Z.-Y. (2014) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.80 · Cited by 327
Covalent inhibitors design and discovery.
De Cesco, S., Kurian, J., Dufresne, C., Mittermaier, A. K., & Moitessier, N. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.019 · Cited by 315
A safe lithium mimetic for bipolar disorder
Singh, N., Halliday, A. C., Thomas, J. M., Kuznetsova, O. V., Baldwin, R., Woon, E. C. Y., Aley, P. K., Antoniadou, I., Sharp, T., Vasudevan, S. R., et al. (2013) · Nature Communications · doi:10.1038/ncomms2320 · Cited by 258
Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update
Hillebrand, L., Liang, X. J., Serafim, R. A. M., & Gehringer, M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01825 · Cited by 199
Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain
Akçay, G., Belmonte, M. A., Aquila, B., Chuaqui, C., Hird, A. W., Lamb, M. L., Rawlins, P. B., Su, N., Tentarelli, S., Grimster, N. P., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2174 · Cited by 207
Diverse Functional Roles of Reactive Cysteines
Pace, N. J., & Weerapana, E. (2013) · ACS Chemical Biology · doi:10.1021/cb3005269 · Cited by 204
Progress with covalent small-molecule kinase inhibitors
Zhao, Z., & Bourne, P. E. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.035 · Cited by 194
Drug discovery considerations in the development of covalent inhibitors
Mah, R., Thomas, J. R., & Shafer, C. M. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.10.003 · Cited by 193
Bhatia, P., Sharma, V., Alam, O., Manaithiya, A., Alam, P., Kahksha, Alam, M. T., & Imran, M. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112640 · Cited by 181
Angst, D., Gessier, F., Janser, P., Vulpetti, A., Wälchli, R., Beerli, C., Littlewood-Evans, A., Dawson, J., Nuesslein-Hildesheim, B., Wieczorek, G., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01916 · Cited by 172
Keap Calm, and Carry on Covalently
Wilson, A. J., Kerns, J. K., Callahan, J. F., & Moody, C. J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400224q · Cited by 171
Mukherjee, H., Debreczeni, J., Breed, J., Tentarelli, S., Aquila, B., Dowling, J. E., Whitty, A., & Grimster, N. P. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob02028g · Cited by 167
Cee, V. J., Volak, L. P., Chen, Y., Bartberger, M. D., Tegley, C. M., Arvedson, T., McCarter, J. D., Tasker, A. S., & Fotsch, C. H. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01018 · Cited by 172
Structure-Based Virtual Screening Approach for Discovery of Covalently Bound Ligands
Warshaviak, D. T., Golan, G., Borrelli, K. W., Zhu, K., & Kalid, O. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500175r · Cited by 169
Singh, N., & Ecker, G. F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051278 · Cited by 160
Mechanism and In Vitro Pharmacology of TAK1 Inhibition by (5Z)-7-Oxozeaenol
Wu, J., Powell, F., Larsen, N., Lai, Z., Byth, K., Read, J. A., Gu, R.-F., Roth, M., Toader, D., Saeh, J. C., et al. (2012) · ACS Chemical Biology · doi:10.1021/cb3005897 · Cited by 145
Exploring receptor tyrosine kinases-inhibitors in Cancer treatments
Metibemu, D. S., Akinloye, O. A., Akamo, A. J., Ojo, D. A., Okeowo, T. O., & Omotuyi, O. I. (2019) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-019-0035-0 · Cited by 173
Selective and reversible modification of kinase cysteines with chlorofluoroacetamides
Shindo, N., Fuchida, H., Sato, M., Watari, K., Shibata, T., Kuwata, K., Miura, C., Okamoto, K., Hatsuyama, Y., Tokunaga, K., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-018-0204-3 · Cited by 146
Identification and Characterization of an Irreversible Inhibitor of CDK2
Anscombe, E., Meschini, E., Mora-Vidal, R., Martin, M. P., Staunton, D., Geitmann, M., Danielson, U. H., Stanley, W. A., Wang, L.-Z., Reuillon, T. D., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.07.018 · Cited by 134
Lysine-Targeted Inhibitors and Chemoproteomic Probes
Cuesta, A., & Taunton, J. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-044805 · Cited by 149
Determining Cysteines Available for Covalent Inhibition Across the Human Kinome
Zhao, Z., Liu, Q., Bliven, S. E., Xie, L., & Bourne, P. E. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01815 · Cited by 134
Kalyukina, M., Yosaatmadja, Y., Middleditch, M., Patterson, A. V., Smaill, J. B., & Squire, C. J. (2019) · ChemMedChem · doi:10.1002/cmdc.201800719 · Cited by 130
Fairhurst, R. A., Knöpfel, T. F., Buschmann, N., Leblanc, C., Mah, R., Todorov, M., Nimsgern, P., Ripoche, S., Niklaus, M., Warin, N., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01019 · Cited by 123
Non-kinase targets of protein kinase inhibitors
Munoz, L. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.266 · Cited by 135
Mons, E., Roet, S., Kim, R. Q., & Mulder, M. P. C. (2022) · Current Protocols · doi:10.1002/cpz1.419 · Cited by 138
Mons, E., Jansen, I. D. C., Loboda, J., van Doodewaerd, B. R., Hermans, J., Verdoes, M., van Boeckel, C. A. A., van Veelen, P. A., Turk, B., Türk, V., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b11027 · Cited by 128
Covalent‐Allosteric Kinase Inhibitors
Weisner, J., Gontla, R., Westhuizen, L. V. D., Oeck, S., Ketzer, J., Janning, P., Richters, A., Mühlenberg, T., Fang, Z., Taher, A., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201502142 · Cited by 135
Activity-based protein profiling: Recent advances in medicinal chemistry
Deng, H., Lei, Q., Wu, Y., He, Y., & Li, W. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112151 · Cited by 126
Recent advances in the development of covalent inhibitors
Kim, H., Hwang, Y. S., Kim, M., & Park, S. B. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00068c · Cited by 116
Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach
Engel, J., Richters, A., Getlik, M., Tomassi, S., Keul, M., Termathe, M., Lategahn, J., Becker, C., Mayer‐Wrangowski, S. C., Grütter, C., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01082 · Cited by 123
The Human Kinome and Kinase Inhibition
Duong‐Ly, K. C., & Peterson, J. R. (2013) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph0209s60 · Cited by 137
Bernetti, M., Cavalli, A., & Mollica, L. (2017) · MedChemComm · doi:10.1039/c6md00581k · Cited by 120
Modjtahedi, H., Cho, B. C., Michel, M. C., & Solca, F. (2014) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-014-0967-3 · Cited by 118
Recent progress on third generation covalent EGFR inhibitors
Cheng, H., Nair, S. K., & Murray, B. W. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.02.067 · Cited by 116
1,3,5-Triazine as a Modular Scaffold for Covalent Inhibitors with Streamlined Target Identification
Banerjee, R., Pace, N. J., Brown, D. R., & Weerapana, E. (2013) · Journal of the American Chemical Society · doi:10.1021/ja400427e · Cited by 108
Avoiding drug resistance in HIV reverse transcriptase
Cilento, M. E., Kirby, K. A., & Sarafianos, S. G. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00967 · Cited by 106
Brameld, K. A., Owens, T. D., Verner, E., Venetsanakos, E., Bradshaw, J. M., Phan, V. T., Tam, D., Leung, K., Shu, J., LaStant, J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00360 · Cited by 96
Type II Kinase Inhibitors: An Opportunity in Cancer for Rational Design
Blanc, J., Geney, R., & Menet, C. J. (2013) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520611313050008 · Cited by 111
Schroeder, R. L., Stevens, C. L. K., & Sridhar, J. (2014) · Molecules · doi:10.3390/molecules190915196 · Cited by 177
Proteome-wide Map of Targets of T790M-EGFR-Directed Covalent Inhibitors
Niessen, S., Dix, M. M., Barbas, S., Potter, Z. E., Lu, S., Brodsky, O., Planken, S., Behenna, D. C., Almaden, C., Gajiwala, K. S., et al. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.08.017 · Cited by 99
The design and development of covalent protein-protein interaction inhibitors for cancer treatment
Cheng, S.-S., Yang, G.-J., Wang, W., Leung, C.-H., & Ma, D.-L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00850-0 · Cited by 98
Planken, S., Behenna, D. C., Nair, S. K., Johnson, T. O., Nagata, A., Almaden, C., Bailey, S., Ballard, T. E., Bernier, L., Cheng, H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01894 · Cited by 97
Cheng, H., Nair, S. K., Murray, B. W., Almaden, C., Bailey, S., Baxi, S. M., Behenna, D. C., Cho-Schultz, S., Dalvie, D., Dinh, D. M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01633 · Cited by 101
Modeling covalent-modifier drugs.
Awoonor-Williams, E., Walsh, A. G., & Rowley, C. N. (2017) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2017.05.009 · Cited by 90
Engel, J., Lategahn, J., & Rauh, D. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00475 · Cited by 101
JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification
Sun, W., Xie, Z., Liu, Y., Zhao, D., Wu, Z., Zhang, D., Lv, H., Tang, S., Jin, N., Jiang, H., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1023 · Cited by 91
McAulay, K., Hoyt, E. A., Thomas, M. C., Schimpl, M., Bodnarchuk, M. S., Lewis, H. J., Barratt, D. G., Bhavsar, D., Robinson, D. M., Deery, M. J., et al. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b13391 · Cited by 91
Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy
Pang, X., Liu, X., Liu, Y., Liu, W., Li, Y.-R., Yu, G.-X., Tian, X., Zhang, Y., Song, J., Jin, C., et al. (2021) · Molecules · doi:10.3390/molecules26144250 · Cited by 85
Pseudokinases: Update on Their Functions and Evaluation as New Drug Targets
Byrne, D. P., Foulkes, D. M., & Eyers, P. A. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0207 · Cited by 89
Xia, G., Chen, W., Zhang, J., Shao, J., Zhang, Y., Huang, W., Zhang, L., Qi, W., Sun, X., Li, B., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5014659 · Cited by 80
The Use of Conformational Restriction in Medicinal Chemistry
Pinheiro, P. D. S. M., Rodrigues, D. A., Maia, R. D. C., Thota, S., & Fraga, C. A. M. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190712205025 · Cited by 85
Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer
Carmi, C., Mor, M., Petronini, P. G., & Alfieri, R. R. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.07.031 · Cited by 92
Design strategies to address kinetics of drug binding and residence time
Cusack, K. P., Wang, Y., Hoemann, M. Z., Marjanovic, J., Heym, R. G., & Vasudevan, A. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.02.027 · Cited by 80
Solubility and Bioavailability Enhancement of Oridonin: A Review
Zhang, Y., Wang, S., Dai, M., Nai, J., Zhu, L., & Sheng, H. (2020) · Molecules · doi:10.3390/molecules25020332 · Cited by 84
Designing Irreversible Inhibitors—Worth the Effort?
González‐Bello, C. (2016) · ChemMedChem · doi:10.1002/cmdc.201500469 · Cited by 74
Birkholz, A. B., Kopecky, D. J., Volak, L. P., Bartberger, M. D., Chen, Y., Tegley, C. M., Arvedson, T., McCarter, J. D., Fotsch, C. H., & Cee, V. J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00749 · Cited by 78
The expanding repertoire of covalent warheads for drug discovery
Mehta, N. V., & Degani, M. S. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103799 · Cited by 86
Tumor‐Targeting of EGFR Inhibitors by Hypoxia‐Mediated Activation
Karnthaler‐Benbakka, C., Groza, D., Kryeziu, K., Pichler, V., Roller, A., Berger, W., Heffeter, P., & Kowol, C. R. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403936 · Cited by 72
Podoll, T., Pearson, P. G., Evarts, J., Ingallinera, T., Бибикова, Е., Sun, H., Gohdes, M. A., Cardinal, K. A., Sanghvi, M., & Slatter, J. G. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.084459 · Cited by 74
Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation
Goodwin, N. C., Cianchetta, G., Burgoon, H. A., Healy, J. P., Mabon, R., Strobel, E. D., Allen, J., Wang, S., Hamman, B. D., & Rawlins, D. B. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500242y · Cited by 70
Bollinger, M. K., Agnew, A. S., & Mascara, G. P. (2017) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155217712401 · Cited by 74
Ma, X., Lv, X., & Zhang, J. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.049 · Cited by 75
Exploiting Atropisomerism to Increase the Target Selectivity of Kinase Inhibitors
Smith, D. E., Marquez, I., Lokensgard, M. E., Rheingold, A. L., Hecht, D., & Gustafson, J. L. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201506085 · Cited by 71
Recent progress in covalent warheads for in vivo targeting of endogenous proteins
Shindo, N., & Ojida, A. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116386 · Cited by 71
Uitdehaag, J. C. M., de Man, J., Willemsen‐Seegers, N., Prinsen, M. B. W., Libouban, M. A. A., Sterrenburg, J. G., de Wit, J. J. P., de Vetter, J. R. F., de Roos, J. A. D. M., Buijsman, R. C., et al. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.05.014 · Cited by 64
New Aminoimidazoles as β-Secretase (BACE-1) Inhibitors Showing Amyloid-β (Aβ) Lowering in Brain
Gravenfors, Y., Viklund, J., Blid, J., Ginman, T., Karlström, S., Kihlström, J., Kolmodin, K., Lindström, J., von Berg, S., von Kieseritzky, F., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300991n · Cited by 70
Li, X., Zuo, Y., Tang, G., Wang, Y., Zhou, Y., Wang, X., Guo, T., Xia, M., Ding, N., & Pan, Z. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4017762 · Cited by 63
Targeting Epigenetic Regulators with Covalent Small-Molecule Inhibitors
Zhang, Y., Rong, D., Li, B., & Wang, Y. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02055 · Cited by 63
Furman, R. R., Byrd, J. C., Owen, R. G., O'Brien, S. M., Brown, J. R., Hillmen, P., Stephens, D. M., Chernyukhin, N., Lezhava, T., Hamdy, A., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01252-y · Cited by 64
Ferlenghi, F., Scalvini, L., Vacondio, F., Castelli, R., Bozza, N., Marseglia, G., Rivara, S., Lodola, A., Monica, S. L., Minari, R., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113786 · Cited by 66
Characterization of FGF401 as a reversible covalent inhibitor of fibroblast growth factor receptor 4
Zhou, Z. M., Chen, X., Fu, Y., Zhang, Y., Dai, S., Li, J., Chen, L., Xu, G., Chen, Z., & Chen, Y. (2019) · Chemical Communications · doi:10.1039/c9cc02052g · Cited by 58
Jiang, M., Huizenga, M. C. W., Wirt, J. L., Pálóczi, J., Amedi, A., van den Berg, R. J. B. H. N., Benz, J., Collin, L., Deng, H., Di, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43606-3 · Cited by 69
How Reactive are Druggable Cysteines in Protein Kinases?
Awoonor‐Williams, E., & Rowley, C. N. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00454 · Cited by 58
Drug design targeting active posttranslational modification protein isoforms
Meng, F., Liang, Z. T., Zhao, K., & Luo, C. (2020) · Medicinal Research Reviews · doi:10.1002/med.21774 · Cited by 61
Pharmacokinetic–pharmacodynamic models that incorporate drug–target binding kinetics
Daryaee, F., & Tonge, P. J. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.03.008 · Cited by 64
Christmann‐Franck, S., van Westen, G. J. P., Papadatos, G., Escudie, F. B., Roberts, A., Overington, J. P., & Domine, D. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00122 · Cited by 62
Chan, A. H., Lee, W., Spasov, K. A., Cisneros, J. A., Kudalkar, S. N., Petrova, Z. O., Buckingham, A. B., Anderson, K. S., & Jorgensen, W. L. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711463114 · Cited by 56
Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S
Lategahn, J., Keul, M., Klövekorn, P., Tumbrink, H. L., Niggenaber, J., Müller, M. P., Hodson, L. E., Flaßhoff, M., Hardick, J., Grabe, T., et al. (2019) · Chemical Science · doi:10.1039/c9sc03445e · Cited by 63
Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter?
Qin, A., Musket, A., Musich, P. R., Schweitzer, J. B., & Xie, Q. R. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab133 · Cited by 66
Taldone, T., Kang, Y., Patel, H. J., Patel, M. R., Patel, P. D., Rodina, A., Patel, Y., Gozman, A., Maharaj, R., Clement, C. C., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401552y · Cited by 53
Biospecific Chemistry for Covalent Linking of Biomacromolecules
Cao, L., & Wang, L. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00066 · Cited by 53
Lategahn, J., Keul, M., & Rauh, D. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201710398 · Cited by 59
Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer
Song, M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501464c · Cited by 54
Reactivity of Covalent Fragments and Their Role in Fragment Based Drug Discovery
McAulay, K., Bilsland, A. E., & Bon, M. (2022) · Pharmaceuticals · doi:10.3390/ph15111366 · Cited by 60
Willemsen‐Seegers, N., Uitdehaag, J. C. M., Prinsen, M. B. W., de Vetter, J. R. F., de Man, J., Sawa, M., Kawase, Y., Buijsman, R. C., & Zaman, G. J. R. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.12.019 · Cited by 51
Zhang, Y., Chen, L., Xu, H., Li, X., Zhao, L., Wang, W., Li, B., & Zhang, X. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.01.090 · Cited by 49
Metadata
- Authors
- Barf, T., & Kaptein, A.
- Affiliations
- Drug Discovery Unit, Covalution Pharma BV, Ravenstein, The Netherlands
- Corresponding author
- Barf, Tjeerd
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2012-06-08
- Volume
- 55
- Issue
- 14
- Pages
- 6243-6262
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2057079741
- Cited by
- 331
- References
- 108
- Citations by year
- 2026: 14 · 2025: 16 · 2024: 21 · 2023: 17 · 2022: 9 · 2021: 30 · 2020: 38 · 2019: 26 · 2018: 22 · 2017: 38 · 2016: 32 · 2015: 22 · 2014: 25 · 2013: 14 · 2012: 7
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- kinase inhibitors, covalent inhibitors, drug development, benefits and risks, kinase-targeted therapy
- MeSH terms
- Animals, Cell Line, Humans, Protein Kinases, Risk, Structure-Activity Relationship, Time Factors, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.